Chemical Optimization Designed to Increase the in vivo Efficacy of HM-27 for the

描述（由申请人提供）：本申请请求资金，以帮助获得必要的额外临床前数据，这些数据是用于治疗多发性骨髓瘤的有前途的新型候选药物商业化所需的。一家名为调制治疗公司的小公司从莫菲特癌症中心获得了这项技术的许可，该公司的员工Priyesh Jain博士与莫菲特癌症中心的Mark McLaughlin博士和Lori Hazlehurst博士合作，并在共同研究者Richard Lush的协助下，提议合成具有更好生物利用度的类似物，并改善或保持对CD44的直接结合亲和力和体外IC50活性。我们将在第一阶段进行初步的PK研究，并在体外和体内验证5TGM1 MM肿瘤生长抑制研究。

DESCRIPTION (provided by applicant): This application requests funds to aid in obtaining the necessary additional preclinical data needed for commercialization of a promising new and novel drug candidate for the treatment of multiple myeloma. A small business, Modulation Therapeutics Incorporated, has licensed this technology from the Moffitt Cancer Center and its employee, Dr. Priyesh Jain, in collaboration with Dr. Mark McLaughlin and Dr. Lori Hazlehurst at Moffitt Cancer Center and aided by co-investigator Richard Lush, PharmD, are proposing to synthesize analogs expected to have better bioavailability and that improve or maintain direct binding affinities for CD44 and in vitro IC50 activity. We will measure preliminary PK studies, and confirmatory in vitro and in vivo 5TGM1 MM tumor growth inhibition studies in Phase 1 of the grant. PUBLIC HEALTH RELEVANCE: This application requests funds to aid a new small business, Modulation Therapeutics Incorporated, in obtaining the necessary additional pre-clinical data needed for commercialization of a promising new and novel drug candidate for the treatment of multiple myeloma. The new drug candidate kills human multiple myeloma tumors, the second most common hematological malignancy in humans, in immune-compromised mice implanted with the human tumor at does that show no obvious toxicity to the mice.